About MedImmune
MedImmune is a Healthcare company based in Gaithersburg (United States) founded in 1987, and was acquired by Astrazeneca in April 2007. Biologic RD for oncology; respiratory, inflammation and autoimmune; and cardiovascular and metabolic diseases. MedImmune has completed 5 acquisitions, including Allozyne, AlphaCore Pharma and Cellective Therapeutics. Its chief executive, as recorded, is Speck Loe. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
MedImmune is a global biologic RD company developing product candidates for three therapeutic areas namely oncology; respiratory, inflammation and autoimmune; and cardiovascular and metabolic disease. It was founded as Molecular Vaccines and has developed Flumist, a nasal spray influenza vaccine which was approved by FDA as a needle-free vaccine CAIV-T in 2007. In April 2007, AstraZeneca acquired MedImmune and since then it is working as its RD unit. In September 2009, MedImmune received approval from the U.S. FDA for its intranasal novel H1N1 influenza vaccine. Currently, it claims to have more than 120 biologics in RD and 40 products in clinical development.
- Headquarters Gaithersburg, United States
- Stage Acquired
- SectorsHealthcare
- Website medimmune.com
- Social LinkedIn X
- Acquired by Astrazeneca (Apr 2007)
- Latest Funding Round$354.18K (USD), Grant
Sep 2018
- InvestorsAstrazeneca
& 1 more
- Investments & AcquisitionsAllozyne
& 4 more
- Acquired byAstrazeneca
(Apr 2007)
Funding Insights of MedImmune
- Total Rounds 4
- Last Round Grant — $354,179
- First Round $805,817
(Jan 2016)
- Investors Count 1
All 4 funding rounds of MedImmune with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2018 | $354,179 | Grant | – | – | |
| Mar 2017 | $670,720 | Grant | – | – | |
| Jan 2017 | $337,270 | Grant | – | – | |
| Jan 2016 | $805,817 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in MedImmune
MedImmune has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Astrazeneca and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Pharmaceutical and biologics products are developed and distributed worldwide. | 1913 | astrazeneca.com | Cambridge, United Kingdom |
Investor details for MedImmune
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MedImmune
1284 people are tracked at MedImmune (770 in leadership, 13 in board & advisors, 501 in team).
| Name | Role | Group |
|---|---|---|
Speck Loe | CEO | Leadership |
Ruud Dobber | EVP & President, BioPharmaceuticals Business | Leadership |
Carla Ruiz Serrano | Human Resources Director | Leadership |
Julia Weigandt | Associate Director, Immunotoxicology | Leadership |
Lan Cao | Head Of Immunology Cell Therapy Discovery | Leadership |
Emma Robbins | Franchise Finance Director - Tagrisso | Leadership |
Bethany Cameron | Director - Business Planning & Operations - Pharmaceutical Sciences | Leadership |
Laurence Somerville | Clinical Account Director | Leadership |
Mickey S. | Sr. Talent Acquisition Partner-commercial Biopharma (rpo) | Leadership |
Avijit Majumdar | Associate Director, Translational Science Lead | Leadership |
Helicia Paz-Chang | Director-translational Sciences Bioanalysis | Leadership |
Maneesh Mishra | Director | Leadership |
Minal Nade-Kulkarni | Director Clinical Operations + RTSM Strategist | Leadership |
Ya G. | Associate Director, Global Analytics & Insights, Oncology | Leadership |
Vickie Beckler | US Lung Ambition Director | Leadership |
David Wright | Senior Talent Acquisition Partner | Leadership |
Jeff Pott | Chief Human Resources Officer, Chief Compliance Officer and General Counsel | Leadership |
Nida Farooq | Healthcare Delivery Partner | Leadership |
Jelena Stanisavljevic | Associate Director, Diagnostic Project Management, Precision Medicine, Oncology | Leadership |
Yen Yin Chiang | Associate Director Data Management Operations | Leadership |
1264 more people are available in the full profile.
Complete people profiles for MedImmune
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MedImmune
MedImmune has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Allozyne, AlphaCore Pharma and Cellective Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provides image analysis and data mining solutions for quantitative digital pathology in the healthcare industry | definiens.com | Munich, Germany | 1994 | Nov 2014 | $150M | |
Protein therapeutics for CNS diseases like multiple sclerosis are developed. | allozyne.com | Seattle, United States | 2005 | Sep 2014 | •••• | |
Antibody-drug conjugates to target cancer stem cells | spirogen.com | London, United Kingdom | 2001 | Oct 2013 | $440M | |
Develops protein therapeutics for treating cardiovascular diseases like atherosclerosis. | alphacorepharma.com | Ann Arbor, United States | 2007 | Apr 2013 | •••• | |
B cell research for cancer and autoimmune diseases was conducted. | cellective.net | Gaithersburg, United States | 2003 | Sep 2005 | •••• |
Complete acquisition details for MedImmune
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of MedImmune
9 dated milestones of MedImmune across 31 years, from founding to its latest funding, stage changes and deals.
- Founded MedImmune is founded.
- Acquisition Acquires Cellective Therapeutics.
- Exit Acquired by Astrazeneca.
- Acquisition Acquires AlphaCore Pharma.
- Acquisition Acquires Spirogen.
- Acquisition Acquires Allozyne.
- Acquisition Acquires Definiens.
- Funding First funding round of $806K.
- Funding Latest funding round, Grant, of $354K.
Competitors of MedImmune
MedImmune has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of MedImmune
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of MedImmune
Websites that share an audience with MedImmune (medimmune.com).
Websites whose visitors overlap most with MedImmune. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| amgen.com | 100% | 495.4K | #116,434 | View details | |
| orexigen.com | 95% | View details | |||
| pfizer.com | 94% | 1.9M | #24,984 | View details | |
arthurdovermd.com | arthurdovermd.com | 84% | – | ||
biophagepharma.net | biophagepharma.net | 84% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 21 similar websites and full traffic analytics for MedImmune
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 21 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as MedImmune (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Medimmune
Complete news archive for MedImmune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MedImmune
MedImmune was founded in 1987 and raised its 1st funding round 29 years after it was founded.
MedImmune is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Speck Loe is the CEO of MedImmune, as recorded in our data.
MedImmune is a global biologic RD company developing product candidates for three therapeutic areas namely oncology; respiratory, inflammation and autoimmune; and cardiovascular and metabolic disease. It was founded as Molecular Vaccines and has developed Flumist, a nasal spray influenza vaccine which was approved by FDA as a needle-free vaccine CAIV-T in 2007. In April 2007, AstraZeneca acquired MedImmune and since then it is working as its RD unit. In September 2009, MedImmune received approval from the U.S. FDA for its intranasal novel H1N1 influenza vaccine. Currently, it claims to have more than 120 biologics in RD and 40 products in clinical development.
MedImmune has made 5 acquisitions, including Allozyne, AlphaCore Pharma, and Cellective Therapeutics.
MedImmune has 2 investors. Key investors include Astrazeneca, and European Union.
Yes. MedImmune was acquired by Astrazeneca in April 2007.